HIV pre-exposure prophylaxis (PrEP)

news

MHRA approves new medicine formulations for HIV prevention

7 May 2024 | By Catherine Eckford (European Pharmaceutical Review)

The authorised formulations are a tablet and a long-acting injection used for preventing sexually transmitted HIV-1 infection (pre-exposure prophylaxis (PrEP).

news

Digital pill tracks HIV prevention pill adherence with 98 percent accuracy

9 December 2021 | By Anna Begley (European Pharmaceutical Review)

Scientists found digital pill systems to be a 98 percent accurate intervention to help men adhere to pre-exposure prophylaxis (PrEP) regimens.

article

HIV treatment evolution: drug development to meet the modern needs of patients

24 September 2021 | By Hannah Balfour (European Pharmaceutical Review)

In this article, European Pharmaceutical Review’s Hannah Balfour explores some of big pharma’s latest developments in HIV treatment, with commentary from ViiV Healthcare’s Head of Research and Development, Kimberly Smith.

news

Gilead files lawsuit against US federal government over alleged contract breaches

1 May 2020 | By Hannah Balfour (European Pharmaceutical Review)

Gilead's complaint alleges five contract breaches by the US Centers for Disease Control and Prevention (CDC) and seeks a declaration of contract breach and damages.

news

New HIV PrEP drug could derail efforts to expand virus prevention coverage

11 March 2020 | By Hannah Balfour (European Pharmaceutical Review)

US researchers have stated a newly approved HIV pre-exposure prophylaxis (PrEP) therapy does not have benefits that warrant its price tag and could deter generic competition.